Literature DB >> 15037268

Cardiac operations in patients with hematologic malignancies.

Alison M Fecher1, Thomas J Birdas, David Haybron, Pavlos K Papasavas, Debbie Evers, Philip F Caushaj.   

Abstract

OBJECTIVES: Patients with hematologic malignancies are frequently in need of major cardiac operations. Previous reports suggest an increased risk for perioperative complications in these immunodeficient patients.
METHODS: Patients diagnosed with any type of hematologic malignancy who underwent open-heart surgery at our institution between 7/1996 and 6/2002 were identified. Their hospital charts were reviewed; demographics, perioperative data and outcomes were recorded.
RESULTS: There were 24 patients (20 men, 4 women); mean age was 68+/-13 years (range 31-84 years). Ten patients had chronic lymphocytic leukemia, seven non-Hodgkin lymphomas, three multiple myeloma and one Hodgkin's disease, chronic myelocytic leukemia, hairy cell leukemia and cutaneous T-cell lymphoma each. The mean pre-operative duration of the hematologic disease was 6.6 years. Twenty-two patients underwent coronary artery bypass grafting (with valve replacement in three patients) and two patients had isolated valve replacement. There was one in-hospital death (4.1%). Twelve patients (50%) had a minor or major complication. Seven reoperations were required-five during the same admission (one for mediastinal bleeding, one for an expanding femoral pseudoaneurysm, one for acute cholecystitis and two for IACD/pacer insertion) and two within 30 days (one for deep sternal wound infection and one for leg wound infection). Mean post-operative stay was 8.2+/-5.8 days and mean ICU stay was 1.6+/-1.1 days. There were three late deaths-two were due to progression of the hematologic disease. The 3-year actuarial survival was 83%.
CONCLUSIONS: Cardiac operations can be performed with acceptable mortality but significant morbidity rates in patients with hematologic malignancies. Bleeding and infectious complications are most frequently seen and usually lead to reoperations. These findings warrant caution during patient selection.

Entities:  

Mesh:

Year:  2004        PMID: 15037268     DOI: 10.1016/j.ejcts.2003.12.006

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Acute leukaemoid reaction following cardiac surgery.

Authors:  Nigel E Drury; Ayyaz Ali; Shafi Mussa; Stephen T Webb; Kanchan P Rege; John Wallwork
Journal:  J Cardiothorac Surg       Date:  2007-01-09       Impact factor: 1.637

2.  Mitral valve repair facilitated with transapical beating heart NeoChord implantation in a non-Hodgkin's lymphoma patient.

Authors:  Ali Sait Kavakli; Raif Umut Ayoglu; Nilgun Kavrut Ozturk; Omer Haldun Tekinalp; Zehra Erkal; Kerem Inanoglu; Mustafa Emmiler
Journal:  J Anesth       Date:  2016-09-19       Impact factor: 2.078

3.  Allogeneic stem cell transplantation in a blast-phase chronic myeloid leukemia patient with carbapenem-resistant Klebsiella pneumoniae tricuspid valve endocarditis: A case report.

Authors:  Bulent Kantarcioglu; Huseyin Saffet Bekoz; Fatih Erkam Olgun; Beytullah Cakal; Burak Arkan; Halil Turkoglu; Ali Mert; Deniz Sargin
Journal:  Mol Clin Oncol       Date:  2016-08-17

4.  Can cardiac surgery be performed safely on patients with haematological malignancies.

Authors:  A Guler; M A Sahin; F Cingoz; E Ozal; U Demirkilic; M Arslan
Journal:  Cardiovasc J Afr       Date:  2012-05       Impact factor: 1.167

5.  Tricuspid Papillary Fibroelastoma Mimicking Tricuspid Vegetation in a Patient with Severe Neutropenia.

Authors:  Kuk Bin Choi; Hwan Wook Kim; Do Yeon Kim; Keon Hyon Jo; Hang Jun Choi; Seok Beom Hong
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2016-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.